The Use of Anagrelide in Myeloproliferative Neoplasms, with Focus on Essential Thrombocythemia

Anagrelide (ANA) is a drug with specific platelet-lowering activity, used primarily in ET, registered as a second-line drug in essential thrombocythemia (ET) in Europe and in some countries as first-line therapy, in USA licensed by FDA for thrombocythemia in myeloproliferative neoplasms (MPN). The p...

Descripción completa

Detalles Bibliográficos
Autor principal: Birgegård, Gunnar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2016
Materias:
Myeloproliferative Disorders (C Harrison, Section Editor)
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5031713/
https://www.ncbi.nlm.nih.gov/pubmed/27497846
http://dx.doi.org/10.1007/s11899-016-0335-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5031713/
https://www.ncbi.nlm.nih.gov/pubmed/27497846
http://dx.doi.org/10.1007/s11899-016-0335-0

Ejemplares similares